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Imran Jalaluddin, DOMS dAbstractA 52 year old male presented with peripheral ulcerative keratitis in the right eye. Patient’s history included retinitis pigmentosa, pseu-
dophakia (right eye), cataract (left eye), bilateral partial deafness, ischemic heart disease, hypertension, type 1 diabetes mellitus,
depression, hyperparathyroidism, hypertriglycemia and renal failure. The patient was on weekly hemodialysis. The peripheral corneal
ulceration remained stable until he developed sudden and rapid thinning after eight months of regular follow up and management.
Laboratory investigations including immunological studies were negative and we had to rely on treatment based on clinical signs,
including the visual acuity, size, depth and staining of the ulcer and perilimbal, episcleral, scleral, corneal and anterior chamber
reactions. The patient was treated with medical and conservative approaches and the eye was protected with a plastic shield
to avoid injury. Despite our efforts, the patient perforated his eye due to a trivial trauma during sleep. He was managed success-
fully with cyanoacrylate glue and a bandage contact lens. The anterior chamber reformed after the perforation was sealed and the
patient is on a regular follow up with a multidisciplinary approach.
Keywords: Peripheral ulcerative keratitis, Immune complex deposition, Peripheral corneal thinning, Impending perforation,
Topical cyclosporine eye drops, Connective tissue diseases, Amniotic membrane transplantation
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Peripheral ulcerative keratitis is a rare condition with the
potential for significant visual morbidity and potential loss
of the eye. The presentation and management can be com-
plicated by underlying diseases such rheumatoid arthritis
(RA), wegener’ granulomatosis (WG), polyarteritis nodosa
(PAN), systemic lupus erythematosus (SLE), sarcoidosis, hep-
atitis B and C may also be present 1–3. Often, management of
peripheral ulcerative keratitis involves a multidisciplinary ap-
proach due to the existing co-morbidities. Initial treatment
is usually medical followed by surgical intervention, includingamniotic membrane transplantation10 or tectonic
keratoplasty.11,14
In this case report we present a challenging management
of a patient with peripheral ulcerative keratitis, highlighting
our management strategies. This case report presents the
treatment in the scenario of multi-systemic disorders and sev-
eral resource constraints.Case presentation
A 52 year old Saudi male, with a known history of retinitis
pigmentosa and partial deafness since childhood, presentede:
al.com
, Saudi
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sion in the right eye. He gave a vague history of trauma in the
right eye during childhood which was found to be insignifi-
cant. He had undergone cataract surgery in the right eye,
with an IOL implant, 8 yr ago, at another health facility in Jed-
dah, Saudi Arabia. He was on insulin for type 1 diabetes mel-
litus for the last 13 years. His hypertension was controlled
with medications for the last 7 years. He also had ischemic
heart disease and had undergone coronary artery bypass sur-
gery (CABG) 2 years ago. He was on weekly hemodialysis for
chronic renal failure for the last 4 years. He was also known to
have hyperparathyrodism and hypertriglycemia and was
being managed by a medical specialist. He was using topical
preparations for pruritus prescribed by a dermatologist. The
patient seemed to be mildly depressed and was referred to
the psychiatrist for management.
He was married and had five healthy children. There was
no family history of night blindness or deafness in the rest
of his family. He was a non-smoker and had no known aller-
gies. For his systemic ailments, he was using caps alfacalcidol
1 OD, tab carvedol 25 mg BD, tab isosorbide dinitrate 10 mg
BD, tab asprin 81 mg OD, tab folic acid 10 mg OD, tab sevel-
amer hydrochloride 800 mg BD, tab simvastatin 20 mg OD,
tab ranatidine 150 mg BD, tab gemfibrozol 600 mg BD, tab
Ca-Co3 600 mg TDS, tab methyldopa 250 mg TDS, tab irbe-
sartan 300 mg OD, tab resperidone 2 mg OD, and injection
epoetin alfa 4000 IV once weekly.
On the first ocular examination, last year, the visual acuity
was 20/150 SC (not improving with pinhole) and 20/100 SC
(20/50 CC). The cornea showed a crescent shaped area of
10  2 mm thinning with a constant estimated depth of
20%. There was no fluorescein staining. The ulcer was located
between 5 and 11 o’clock in the right eye (Fig. 1). The over-
lying epithelial edge was sloping and not overhanging. No
vessels were bridging the defect. There was no corneal infil-
trate and the anterior chamber was quiet. The sclera was not
involved. The examination of the left eye showed early cata-
ract. Fundus examination revealed advanced retinitis pig-
mentosa in both eyes. The visual fields were severely
constricted (Fig. 2) consistent with retinal findings. Routine
phacoemulsification surgery with foldable IOL was planned
for the left eye, but was postponed due to delayed fitness
by the cardiologist who wanted to see his latest echocardio-
gram. At 5 month follow up, the right eye and the vision re-
mained relatively stable, with no change in the size and the
depth of the initial lesion. Several systemic laboratory tests
(basic and immunological) were performed and were all
negative.
After nine months from initial presentation, with the pa-
tient being asymptomatic on a routine follow up visit, mild
episcleritis was noticed at the 9 o’clock position in the right
eye. Prednisolone Acetate Ophthalmic Suspension (1%) QFigure 1. Peripheral Ulcerative Keratitis – (Rt) eye.4 h was prescribed and inflammation was controlled within
10 days. The patient was maintained on topical 0.1% fluoro-
metholone eye drops Q 4 h for another 10 days, then the
drops were reduced to Q 12 h for another fortnight. Episcle-
ritis resolved completely and was not present at the subse-
quent, regular 3 weekly visits.
4 months later, his wife noticed an unusual redness in his
right eye. The patient noted some reduction in vision, with-
out any pain, so he chose to ignore it. When his symptoms
did not improve over the next three days he presented to
our ophthalmic department. On examination, the vision in
the right eye was reduced to counting fingers at 1 m. There
was an exacerbation in the perilimbal inflammation, associ-
ated with further corneal thinning and mild scleritis. There
was no infiltrate and the anterior and posterior chambers
were quiet, and there was no RAPD. An area of thinning of
0.5  0.5 mm along the limbus at 7 o’clock involving roughly
70% of depth of the stroma developed suddenly within the
next 3 days (Fig. 3). There was no descemetocele and no
endothelial folds. Corneal sensations were intact and equivo-
cal in both eyes. The sudden thinning prompted us to post-
pone the surgery in the left eye until the right eye could be
managed and stabilized.
Again, several laboratory investigations were urgently per-
formed and most were negative. The results of the laboratory
investigations were: CBC: Hgb: 13.9 g/dl, WBC: 7.89  103/
ll (normal), ESR: 34 mm/hr at the end of 1 h, HCT: 39.30%
(Normal), RBC: 4.22  106/lL (decreased), MCH: 30.30 pg
(normal), MCHC: 32.6 g/dl (normal), MCV: 93.1 fl (normal),
PLT: 260  103/ll, RDW-CV: 15.8% (11.6–14.4), Immunolog-
ical Testing: Serum R.A. factor: negative (<8 iu/m), serum C-
reactive protein (CRP): negative (<0.8 mg/dl), ANA by ELISA:
6.8 units which means negative (range < 20 negative, 20–60
moderately positive, >60 strong positive), serum ANCA: C-
ANCA: 4.1 units, P-ANCA: 1.9 units, which means both were
negative (range < 20 negative, 21–30 moderately positive,
>30 strong positive), serum ACE levels were within normal
limits, serum anti-CCP antibody requested by the rheumatol-
ogist (normal). Blood Chemistry: serum AST: 14 l/l, serum
BUN: 97.5 mg/dl, serum Creatinine: 9.39 mg/dl ("""), serum
glucose (fasting): 119.3 mg/dl, serum K+: 4.97 mmol/L, ser-
um Na+: 139.9, serum VDRL (syphilis serology): negative,
Hepatitis B and C Serology: negative; Chest X-Ray PA view,
no lung lesions were present.
Therefore, our earlier diagnosis of ‘‘idiopathic peripheral
ulcerative keratitis (PUK) – (Right Eye)’’ was revised to
‘‘idiopathic PUK with impending perforation OD with pseu-
dophakia and cataract OS with advanced RP OU’’.Management
Initially, we prescribed fluorometholone eye drops (0.1%) Q
12 h or Q 6 h (modified based on the waxing and waning of the
injection around the lesion) and lubricants Q 4 h. A close fol-
low-up was kept and the ulcer remained stable. Sizes, depth
of thinning and staining and various ocular inflammatory reac-
tions were noted overtime. There was no evidence of uveitis,
throughout. Corneal infection/abscess was ruled out repeat-
edly. Dry eye and blepharitis were not present.
At the time of sudden exacerbation which set in, as men-
tioned above, a careful history was re-taken and a repeated
systemic examination was carried out just in case some signs
Figure 2. Visual Fields 30-2 (both eyes).
Figure 3. Pinhead size peripheral thinning (no perforation) – (Rt) eye.
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any ocular trauma was repeatedly discussed with the patient
and his attendants and he was advised to use a plastic shield
especially at night over his right eye. A rheumatologist was
consulted and investigations were performed to rule out
any associated autoimmune disease. Oral methotrexate,
cyclosporine and tetracycline and high dose of steroids were
discussed with the rheumatologist but could not be started
as the patient had impaired renal functions and was on
hemodialysis. Based on the systemic condition there were
very few options left for medical treatment of the ophthalmic
condition. However, with a safety margin in mind, a low dose
course of oral steroids at 10 mg per day was started. Topical
steroids were not started due to risk of super-infection and
inherent risk of thinning associated with topical steroid
use.6 Topical NSAIDS were avoided, as there are reports of
corneal melting associated with their use. Culture and smear
of the lesion showed no growth of any organism.
Cyclosporine (2%) eye drops were advised but were not
available in this concentration in various pharmacies. Hence,a concentration of cyclosporine (0.05%) (Rhestasis) Q 4 hourly
which were available were commenced and used for 6 days,
with an intention of providing some anti-cytotoxic action of
cyclosporine.9 However, the patient developed corneal toxic-
ity, seen as punctate epithelial erosions (Fig. 4). The dosage
was reduced to QID which was well tolerated and continued
until higher concentrations were arranged from another city.
Newer agents13 such as topical 1% medroxyprogesterone or
topical 20% N-acetylcysteine were not available.
The rate of thinning continued unabated. The depth of ul-
cer increased to 75% within three days with the adjacent
sclera showing a pinhead sized translucency on retro-illumi-
nation (Fig. 3). Betaxolol eyedrops 0.5% were added to re-
duce IOP and the use of plastic shield was again
emphasized (something which the patient did not like to
use), but there was no better alternative to prevent acciden-
tal trauma. IOP measurement was not performed to avoid
inadvertent iatrogenic trauma. Considering the thinning
and possibility of an impending spontaneous perforation, a
second opinion was sought from two neighboring centers
where observation and the same management were advised.
Considering the friability of the tissues and active inflamma-
tion, any surgical intervention was likely to fail or invoke sub-
sequent surgically induced necrotizing scleritis with a
possibility of loss of remaining vision and the eye itself.
Unfortunately, the patient sustained trauma while asleep
as he forgot to wear the plastic shield. He had either rubbed
or hit his eye and developed a small perforation. He pre-
sented to us the next day and we used cyanoacrylate glue
to seal the micro-perforation and a bandage contact lens
was placed to act as a truss. The small corneal defect was
sealed and the anterior chamber reformed. Another senior
Figure 4. Punctate epithelial erosions- drug toxicity – (Rt) eye.
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transplantation (AMT) was suggested especially if the perfo-
ration recurred or increased in size due to an autoimmune
process. However our management and regular follow up
were accepted as correct under protracted circumstances
documented above.
The corneal ulcer was stabilized with topical cyclosporine
(2%) eye drops twice daily, betaxolol (0.5%) eye drops, lubri-
cant eye drops, low dose oral steroids (10 mg OD) and low
dose caps doxycycline (100 mg OD) and oral tab ascorbic
acid (vitamin C) 500 mg for 3 weeks. Thereafter, cyclosporine
(2% eye drops) was replaced with cyclosporine (1%) eye
drops and continued for 6 weeks. Oral doxycycline was
stopped at 6 weeks and steroids were tapered.
At six months of follow up, the corneal ulcer remained stable
with acceptable scarring and a patent anterior chamber, with
the patient having a vision of 20/250 OD. He was followed up
regularly every 2 weeks at the time of clarking. He continued
to undergo hemodialysis once a week and had regular follow
up with his cardiologist, rheumatologist and the dermatolo-
gist. The plastic shield was used continuously.
Discussion
The central cornea derives oxygen from ambient air
through the tear film and aqueous humor. In contrast, the
peripheral cornea receives oxygen and nutrients from the
perilimbal capillary arcades (in addition to the tears and
aqueous humor). The proximity of corneal tissue to this vas-
cular and lymphatic arcade readily exposes the peripheral
cornea to inflammatory cells and mediators1 which can cause
peripheral ulcerative keratitis (PUK). It might be expected
that antigen-antibody complexes, may activate complement
more effectively in the peripheral cornea compared to the
central cornea. The resultant attraction of inflammatory cells
including neutrophils and macrophages may release proteo-
lytic and collagenolytic enzymes causing destruction and
thinning2 of the stroma in the peripheral cornea. Several sys-
temic conditions are associated with PUK,3 these include
infective causes and autoimmune causes such rheumatoid
arthritis, wegeners granulomatosis, systemic lupus erythema-
tosus, polyarteritis nodosa,4 syphilis, sarcoidosis, hepatitis C
and sweet’s syndrome.12
Diagnosing systemic diseases entails a battery of tests2,3
on the patient to identify the cause. The authors adviseclinicians to carry out the baseline tests first and progress
to the more expensive and costlier tests based on the results
of the initial tests. For example, we tested serum RA factor
first and when it was negative, serum anti-CCP (cyclic citrulli-
nated peptide antibodies) was ordered.
The mainstay of treatment is aimed at preventing or reduc-
ing corneal damage. Systemic therapy is aimed at controlling
the underlying disease. The goal is re-epithelialization of the
epithelial defect to halt progressive corneal ulceration. As
our patient had multisystem disorders, our therapeutic options
were very limited. Oral steroids6 are recommended as sys-
temic treatment in full dose (1 mg/kg body weight) however
our patient had diabetes and renal impairment warranting a
reduction in dose. Topical steroids such as prednisolone ace-
tate reduce inflammatory activity3 but are associated with
the inherent risk of corneal thinning as they inhibit collagen
activity and can cause a super-infection and should be avoided
in a patient similar to ours. Oral tetracyclines are known to have
anti-collagenase activity7 and are recommended, Doxycycline
which can be given in a dose of 200 mg OD. However dose
reduction to 100 mg is required in patients such as ours with
chronic renal failure. Oral methotrexate and cyclosporine are
avoided in a patient with renal dialysis (based on the discussion
with rheumatologists). Vitamin C helps in laying down colla-
gen8 and its use is encouraged. Topical cyclosporine seems
to be a drug of choice.9 Newer drugs such as topical medrox-
yprogesterone (1%) eye drops,13 (which inhibits collagenase
synthesis) or topical N-acetylcysteine13 (20%) eye drops (a
competitive inhibitor of collagenase) have also been used for
managing similar cases.
Tissue glue3,5,14 (cyanoacrylate adhesive) was used for
sealing the micro-perforation, and a bandage contact lens3,5
was used as a truss and to help epithelial healing. Amniotic
membrane transplant3,10 may be warranted if all other treat-
ments fail. Tectonic keratoplasty3,11,14 may also be used in
advanced cases warranting extensive surgery14. The patient
should be advised to avoid trauma. Spontaneous perforation
is rare (except in the severest form called the corneal melt
syndrome).
One of the strongest differential diagnoses in our case was
Mooren’s ulcer2 but was ruled out due to the presence of
scleritis, lack of pain, lack of overhanging edge and laterality
(especially considering patient’s age). The other strong
possibility in diagnosis was PUK associated with polyarteritis
nodosa (PAN)2–4,13 and a suggestion to consider this diagno-
sis was recommended by us to the rheumatologists as PAN is
associated with such multisystemic disorders such as hyper-
tension, myocardial infarction, renal failure, CNS and skin
problems.
It is concluded, therefore, that the management of such
cases, underscores the need for a detailed workup, regular
follow up and close teamwork with other specialties and
consultation with senior colleagues. The patient must be ad-
vised to avoid trauma, and to use a plastic shield over the
affected eye especially while asleep. The unpredictable nat-
ure of PUK, at times (especially if the underlying cause cannot
be identified) may entail the treating physician to counsel the
patient towards a guarded prognosis and the requirement
for further surgical interventions such as AMT and tectonic
keratoplasty.
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